Drug intelligence / Profile preview

Diclofenac + Methotrexate

Development stage: Unknown
Lead developer: Novartis
Modality: Small Molecules
Administration: Oral

Overview

The combination of diclofenac and methotrexate refers to the co-administration of these two separate medications, frequently for patients with rheumatoid arthritis and other inflammatory conditions. Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation in conditions like osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. Methotrexate is classified as an antineoplastic agent, a disease-modifying antirheumatic drug (DMARD), and an immunosuppressant, primarily used for treating rheumatoid arthritis, psoriasis, and various cancers.

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)DHFR (Dihydrofolate reductase)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on Diclofenac + Methotrexate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Diclofenac + Methotrexate.

Explore the full profile